GlassScriptPhysician profile
Geetha Mohan
NPI 1316927668
$5,172.23
in general payments reported to CMS, 2019-2025
33 companies · $260 in 2025
The $260 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $838 · 2020: $663 · 2021: $1,304 · 2022: $539 · 2023: $951 · 2024: $616 · 2025: $260.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,828.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,828.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,367.78 | 2021-2024 | Onyx Frontier, Launcher, Euphora |
| Janssen Pharmaceuticals, INC | $606.91 | 2019-2023 | Xarelto |
| Abbott Laboratories | $597.59 | 2019-2025 | Mitraclip |
| Abiomed | $354.72 | 2019-2023 | Impella |
| Novartis Pharmaceuticals Corporation | $343.79 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $258.76 | 2020-2024 | Farxiga |
| E.R. Squibb & Sons, L.L.C. | $202.67 | 2019-2024 | Eliquis |
| Esperion Therapeutics, INC. | $183.73 | 2021-2025 | Nexletol |
| Novo Nordisk INC | $160.98 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $156.50 | 2019-2025 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $125.00 | 2019 | |
| Janssen Scientific Affairs, LLC | $124.42 | 2019 | |
| Amgen INC. | $123.38 | 2019-2024 | Repatha |
| Pfizer INC. | $80.91 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $58.16 | 2019-2021 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $48.29 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $45.00 | 2019-2021 | |
| Kestra Medical Technology Services, INC. | $41.43 | 2025 | Assure Wcd |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $33.40 | 2021-2023 | Lifevest |
| Kowa Pharmaceuticals America, INC. | $31.46 | 2021 | |
| Cardiovascular Systems INC. | $27.72 | 2019 | |
| Convatec INC. | $22.11 | 2024 | |
| Merck Sharp & Dohme LLC | $21.59 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $20.71 | 2025 | Opsynvi |
| Chiesi USA, INC. | $20.42 | 2024 | Kengreal, Cleviprex |
| Boston Scientific Corporation | $18.13 | 2021 | |
| United Therapeutics Corporation | $17.08 | 2021 | |
| Atricure, INC. | $16.33 | 2024 | |
| Cardiva Medical, INC. | $15.58 | 2021 | |
| Philips North America LLC | $14.86 | 2020 | |
| Amarin Pharma, INC. | $14.70 | 2021 | |
| Aegerion Pharmaceuticals, INC. | $13.46 | 2019 | |
| Merit Medical Systems INC | $4.66 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Geetha Mohan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.